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Abstract
Introduction. The aim of this study was to determine the prognostic value of
the first urinary albumin/creatinine ratio (ACR) for adverse maternal and
neonatal outcomes and how it relates to other prognostic factors. Material and
methods. We performed a retrospective cohort study from December 2009 to
February 2012 with analysis of demographic, clinical and biochemical data
from two obstetric day assessment units in hospitals in Southeast Scotland. We
included 717 pregnant women, with singleton pregnancies after 20 weeks’
gestation, referred for evaluation of suspected preeclampsia and having their
first ACR performed. The ability of ACR to predict future outcomes was
assessed in both univariable and multivariable logistic regression models. The
latter assessed its prognostic value independent of (adjusting for) existing
prognostic factors. Primary outcome measures were maternal and neonatal
composite adverse outcomes, and a secondary outcome was gestation at
delivery. Results. In all, 204 women (28.5%) experienced a composite adverse
maternal outcome and 146 women (20.4%) experienced a composite adverse
neonatal outcome. Multivariate analysis of log-transformed ACR demonstrated
that a 1-unit increase in log ACR is associated with an increased odds of
adverse maternal [odds ratio 1.60, 95% confidence interval (CI) 1.45–1.80] and
adverse neonatal (odds ratio 1.15, 95% CI 1.02–1.29) composite outcomes, and
with reduced gestational age at delivery (coefficient: 0.46, 95% CI 0.54 to
0.38). Conclusions. ACR is an independent prognostic factor for maternal
and neonatal adverse outcomes in suspected preeclampsia. ACR may be useful
to inform risk predictions within a prognostic model.
Abbreviations: ACR, albumin to creatinine ratio; BMI, body mass index; BP,
blood pressure; CI, confidence interval; MAP, mean arterial blood pressure;
OR, odds ratio; RR, risk ratio.
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Introduction
Preeclampsia is defined as the presence of raised blood
pressure (BP; ≥140/90 mmHg) after 20 weeks’ gestation,
in a previously normotensive non-proteinuric patient
with one or more of the following: significant protein-
uria (≥0.3 g/24 h), maternal organ dysfunction or utero-
placental dysfunction (1,2). Suspected preeclampsia is
the most frequent clinical presentation to obstetric
units. Preeclampsia is associated with severe complica-
tions such as seizures, stroke, multiple organ failure and
perinatal mortality if not recognized and managed
properly.
The spot urinary protein to creatinine ratio and the
albumin to creatinine ratio (ACR) have been studied in
patients with renal disease, diabetes and preeclampsia to
assess proteinuria. Albumin excretion is considered to
reflect glomerular damage more accurately than total pro-
tein excretion, and albuminuria may be a marker of sys-
temic endothelial cell dysfunction (3). The majority of
international organizations now recommend spot protein-
uria tests in the assessment of suspected preeclampsia.
ACR has been shown to be an accurate indicator of pro-
teinuria in women with preeclampsia (4–6). Despite this
evidence, the obstetric community has not widely
adopted the use of ACR as yet, and protein to creatinine
ratio or 24-h urine collection are more commonly
employed.
As well as being useful in the diagnosis of preeclampsia
(4,6), ACR has potential to be useful in predicting
adverse pregnancy outcomes (7,8). New prognostic fac-
tors are needed in this area (9–12). Prognostic factors can
guide clinical decision-making and patient counseling,
and inform the design and analysis of new trials (10–12).
They can also improve prognostic models, which produce
absolute risk predictions for women based on a set of
individual characteristics (9). Before including a new fac-
tor in a prognostic model, it is important to quantify its
independent prognostic value over and above existing
prognostic factors. Factors that add additional (indepen-
dent) prognostic information are difficult to find, but are
necessary to improve the discrimination performance of
prognostic models (12).
The aim of this study was to examine the prognostic
value of baseline ACR (ACR at first presentation) to pre-
dict maternal and neonatal adverse outcomes in women
referred with suspected preeclampsia. There were two
objectives: (i) to examine whether ACR is prognostic for
adverse maternal and neonatal outcomes when no other
factor is considered (unadjusted prognostic effect) and
(ii) to evaluate whether ACR is a prognostic factor for
such outcomes after adjusting for existing prognostic fac-
tors (independent prognostic effect).
Material and methods
Study design
We performed a retrospective cohort study of pregnant
women undergoing ACR test in the obstetric Day Assess-
ment Units of two hospitals in National Health Service
Lothian trust between December 2009 and February 2012.
The Simpson Centre for Reproductive Health is a tertiary
referral center with more than 6500 deliveries per annum.
St John’s Hospital is a district general hospital with
approximately 2600 deliveries per annum. Women were
excluded if they had not delivered by the end of February
2012.
All pregnant women with urinary ACR results were
identified from a biochemistry database (APEX,
ApexHealthware). Women were included if they had
booked for their pregnancy prior to 14 weeks and if they
were referred from primary care to the hospital Day
Assessment Unit with suspected preeclampsia [suspected
hypertension (generally ≥140/90 mmHg) and at least 1+
proteinuria on dipstick testing]. Women were excluded if
they had multiple pregnancy, proteinuric renal disease or
proven urinary tract infection, or if the ACR was mea-
sured for another indication (for example diabetes).
Women who had their first ACR sent prior to 20 weeks’
gestation were also excluded, as this suggests a chronic
hypertensive or proteinuric disorder or underlying renal
pathology.
We performed systematic review of medical records
collecting predefined characteristics (demographic and
clinical) to maximize accuracy and minimize missing
data. We used multiple data sources to collect neonatal
outcome data in order to increase confidence that no
cases of perinatal mortality or significant morbidity were
missed. Data were acquired from the maternity electronic
patient records database TRAK (supplied by Intersystems)
and the neonatal unit electronic patient records database
BadgerNet (supplied by Clevermed) systems. Demo-
graphic features were recorded at booking visit, clinical
and laboratory data at the time of first ACR measurement
and subsequent antenatal visits and at delivery, and the
Key Message
Albumin to creatinine ratio is an independent prog-
nostic factor for maternal and neonatal adverse out-
comes in suspected preeclampsia, though the
prognostic value appears larger for maternal out-
comes. Therefore albumin to creatinine ratio could
play an important role in healthcare research and
clinical practice in the future.
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outcome of mothers and babies was collected for every
pregnancy.
ACR measurement taken on first hospital assessment
for suspected preeclampsia was used in the analysis (i.e.
follow-up measurements were not included). ACR was
calculated from urine samples in the biochemistry labs of
The Royal Infirmary of Edinburgh. Immunoassays
(Abbott Architect), turbidmetric and kinetic alkaline
picrate (Jaffe) were used to calculate the concentrations
of albumin and creatinine, respectively, in the urine sam-
ple. From this, the albumin (mg/L)/urine creatinine
(mmol/L) was calculated.
Existing prognostic factors were: gestational age at ACR
measurement, essential hypertension, preexisting diabetes,
gestational diabetes, social deprivation index, body mass
index (BMI), mean arterial BP, current smoking status,
parity and maternal age recorded from the clinical record
at booking (<14 weeks). Deprivation was recorded as
social multiple index of deprivation [a postcode-based
Scottish Index of multiple deprivation from 2012 – five
groups ranging from most deprived index (1) to least
deprived index (5)] (13). BMI was recorded as <18.5,
18.5–24.99, 25.0–29.99, 30.0–34.9, 35.0–39.9 and >40.
Mean arterial BP(MAP) was recorded as diastolic BP+ 1/
3 (systolic BP-diastolic BP). MAP was used in place of
systolic or diastolic BP because previous evidence suggests
it is a better prognostic factor for preeclampsia than BP
measured during the first or second trimester of preg-
nancy (14). Data on development of gestational diabetes
(to allow exclusion and diagnosed using Scottish Intercol-
legiate Guidelines network guideline) (15) and gestation
at ACR (days) were also recorded.
The primary maternal outcome was a composite
adverse maternal outcome, defined as one or more of:
use of intravenous magnesium sulfate for seizure prophy-
laxis, use of intravenous antihypertensives, admission to
intensive care unit/or high dependency unit for hyperten-
sion, placental abruption, eclampsia or HELLP (haemoly-
sis, elevated liver enzymes, low platelets). The primary
neonatal outcome was a composite adverse neonatal out-
come, defined as one or more of: iatrogenic preterm
delivery <34 weeks, birthweight <5th centile (calculated
from sex-specific birthweight centile charts) (16), abnor-
mal umbilical artery Doppler [absent or reversed end-dia-
stolic (ARED) flow], arterial cord pH <7.1, need for
ventilation, neonatal or intrauterine death. Secondary
outcome was gestation at delivery (weeks).
No formal power calculation was performed, and we
included all data available over a three-year time period
to maximize sample size. In prognosis research, a typical
rule of thumb is that at least 10 events (cases with the
outcome of interest) are required to evaluate every one
candidate prognostic variable (17). In our study, over 200
women had a maternal composite adverse outcome, thus
the sample size was considered adequate for the analysis
performed.
In all, 3.9% of women had one or more missing values
for data on existing prognostic factors. Due to the small
proportion missing we considered a complete case multi-
variable analysis sufficient (18). Thus, only a complete
case analysis was performed, and the relatively few
women with missing data were excluded from the multi-
variable analysis but included in the ACR-only analysis.
Primary analyses
The baseline characteristics of the sample were summa-
rized by primary outcome status with differences between
groups assessed using unpaired t-tests or Mann–Whitney
U-tests for continuous and chi-square tests for binary
data.
Univariable and multivariable logistic regression models
were used to examine the unadjusted and the adjusted
(independent) prognostic association of ACR with each
binary primary outcome. The multivariable analysis was
adjusted for a predefined set of factors that we considered
to be prognostic factors, as described above.
For the continuous variable “ACR” the assumption of
linearity of the prognostic effect on the log-odds scale
was examined using fractional polynomials. Fractional
polynomials of degree two were used to obtain an appro-
priate transformation for ACR, for which the linearity
assumption did not hold (19). This suggested that a loga-
rithmic transformation was needed for ACR. Thus, the
logistic models estimated the prognostic value of ACR as
summarized by an (adjusted) odds ratio (OR), giving the
(adjusted) relative odds of the outcome for two individu-
als that differ in log-ACR by 1 unit. To avoid deletion of
patients with undefined log-transformed ACR values [log
(0)], 0.01 was added across all the entries of ACR follow-
ing transformation of the data.
Similarly, univariable and multivariable models were
fitted for the secondary outcome, gestation weeks at
delivery using linear rather than logistic regression.
For the neonatal composite outcome, gestational age at
ACR measurement was adjusted for as a binary outcome
after categorizing to age <34 weeks and age ≥34 weeks.
This categorization was enforced by the clinical team in
advance of the analysis as follows:
• Women who had the first ACR test before 34 weeks
represented a group with suspected preterm preeclampsia
vs. women with suspected later onset preeclampsia.
• Preterm preeclampsia is a more severe clinical condi-
tion and is associated more often with neonatal adverse
outcome including premature delivery.
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• Part of the composite adverse neonatal outcome is
iatrogenic preterm delivery prior to 34 weeks.
The rationale for the above was based on the existing
literature (20–23).
Secondary analysis
The discrimination performance of the entire multivari-
able model was summarized to ascertain its potential as a
prognostic model, using the apparent C statistic [area
under the receiver operating characteristic (ROC) curve]
where 0.5 indicates no discrimination (between those
with and those without the outcome) beyond chance and
1 indicates perfect discrimination. The C-statistic is
equivalently defined as the probability that the predicted
risk for a randomly selected individual with the outcome
is higher than that for a randomly selected individual
without the outcome (24).
Sensitivity analysis
Alongside the univariable and multivariable logistic
regression analyses to obtain ORs, Poisson regression with
robust standard errors was used to obtain (adjusted) risk
ratios (RRs). The dataset included extreme values (two
entries ACR = 2000 and one entry where ACR = 0).
Therefore a sensitivity analysis was run to examine the
effect of excluding these values.
All analyses were performed in STATA version 12 (Sta-
taCorp, College Station, TX, USA) and the regression
models fitted using maximum likelihood estimation.
This was a retrospective study on samples already
obtained and the study was approved through the
University of Edinburgh and registered with the Univer-
sity of Edinburgh and NHS Lothian on 29/2/2012. No
external ethics committee was required. An agreement
with the data holder was in place to use the data, for the
purposes of this study, which were anonymous and
unlinked.
Results
In all, 941 pregnant women had an ACR performed dur-
ing the study period. A total of 224 records were
excluded due to predefined exclusion criteria, leaving a
cohort of 717 women. Complete data (on ACR and exist-
ing prognostic factors for the multivariable analysis) was
available for 689 women. Women’s characteristics are
detailed in Table 1. The majority of first ACR measure-
ments were performed between 35 and 40 weeks’ gesta-
tion (interquartile range 35–40 weeks, median 37 weeks
and standard deviation 4 weeks).
Adverse maternal outcomes
Of the 717 women included, 204 experienced a composite
adverse maternal outcome (28.5%) (Table 2). Thirty
women had more than one adverse event (n = 174 one
event, n = 26 two events, n = 4 three events), leading to
a total of 238 adverse outcomes. Supporting Information
Table S1 shows the maternal characteristics for the
women with and without composite adverse maternal
outcomes. MAP and maternal age at booking were com-
parable between the two groups. There was no significant
difference between the two groups regarding essential
hypertension, gestational diabetes, and smoking or social
deprivation index. Univariable analysis showed that mean
ACR, median gestational age at ACR measurement, mean
Table 1. Baseline maternal characteristics (values are numbers and
percentages of the presence of a given characteristic).
Characteristic
Participants
(n = 717)
Maternal age at delivery
(years), mean (SD)
29.93 (6.06)
Booking characteristics
Nulliparity 57.18%
Essential hypertension 9.34%
Preexisting diabetes 2.79%
Current smoker 15.85%
Scottish index of multiple deprivation
1 (most deprived) 21.51%
2 22.63%
3 20.39%
4 15.39%
5 (least deprived) 20.11%
Body mass index
<18.5 2.32%
18.5–24.99 33.48%
25.0–29.99 28.55%
30.0–34.9 20.14%
35.0–39.9 9.71%
>40 5.80%
Booking systolic BP,
mean (SD)
115.26 (12.48)
Booking diastolic BP,
mean (SD)
69.78 (9.81)
Booking mean arterial BP,
mean (SD)
84.94 (9.95)
Development of
gestational diabetes
3.35%
Gestational age at ACR test
(weeks), median (IQR)
37.43 (35.0–39.14)
ACR result (mg/mmol), median (IQR) 4.40 (1.40–23.60)
Gestational age at delivery
(weeks), median (IQR)
39.43 (38.00–40.43)
BP, blood pressure; HDU, high dependency unit; HELLP, hemolysis ele-
vated liver enzymes low platelet count syndrome; ICU, intensive care
unit; IQR, interquartile range; SD, standard deviation.
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maternal age, preexisting diabetes and BMI differed
between the two outcome groups (Table S1).
Adverse neonatal outcomes
Of 717 neonates, 146 experienced a composite adverse
neonatal outcome (20.4%) (Table 2). Twenty-eight neo-
nates had more than one adverse event (n = 118 one
event, n = 15 two events, n = 8 three events and n = 5
four events), leading to a total of 192 adverse outcomes.
Maternal age was comparable between the two groups.
There were differences in median gestational age at ACR
measurement, mean ACR, smoking, BMI and MAP
between the groups (see Supporting Information
Table S2).
Unadjusted and adjusted prognostic value of
ACR for maternal and neonatal adverse
outcomes
Univariable logistic regression analysis of all 717 women
(Table 3) showed that log ACR is prognostic for both
maternal [OR 1.52, 95% confidence interval (CI) 1.38–
1.684] and neonatal (OR 1.13, 95% CI 1.02–1.25) com-
posite adverse outcome. These unadjusted estimates imply
that a unit increase in log-transformed ACR increases the
odds of maternal and neonatal adverse outcomes by 52%
and 13%, respectively.
Multivariable analysis (based on the 689 women with
complete data, Table 3) also showed that log ACR is an
independent prognostic factor for maternal composite
adverse outcome (OR 1.60, 95% CI 1.43–1.80) and
neonatal composite adverse outcome (OR 1.15, 95% CI
1.02–1.29). This implies that a unit increase in log-trans-
formed ACR, after adjusting for other factors, increases
the odds of adverse maternal composite outcome by 60%
and of adverse neonatal outcome by 15%.
Unadjusted and adjusted prognostic value of
ACR for gestation at delivery
Univariable (coefficient 0.38, 95% CI 0.48 to 0.27,
p < 0.001) and multivariable linear regression (coefficient
0.46, 95% CI 0.54 to 0.38, p < 0.001) shows a prog-
nostic effect of log ACR for gestational age at delivery
(Supporting Information Table S3). The adjusted estimate
implies that for every unit increase in log-transformed
ACR, the average gestational age at delivery is decreased
by about 0.5 weeks.
Discrimination performance of the multivariate
models
The apparent C-statistic for the multivariable models was
0.76 (95% CI 0.72–0.80) for composite maternal adverse
outcome and 0.72 (95% CI 0.67–0.77) for composite
neonatal adverse outcome (Table 3). If ACR is removed,
then the C-statistic of the multivariable models is reduced
considerably to 0.67 (95% CI 0.64–0.72) for maternal
composite outcome; however, for the neonatal outcome
the C-statistic and its 95% CI barely change. This suggests
that ACR is more important in terms of providing addi-
tional discrimination as to outcome risk predictions, for
the maternal outcome.
Sensitivity analysis
Results from the Poisson model with robust standard
errors were consistent with those of logistic regression
analysis. In both the univariable and multivariable analy-
sis ACR still had significant prognostic ability for mater-
nal (unadjusted RR 1.31, 95% CI 1.24–1.39; adjusted RR
1.32 95% CI 1.25–1.41) and neonatal outcomes (RR 1.10,
95% CI 1.01–1.19; adjusted RR 1.10, 95% CI 1.02–1.19)
(Supporting Information Table S4). This implies that,
after adjusting for other factors, a unit increase in log-
transformed ACR increases the risk of adverse maternal
outcome by 32% and of fetal adverse outcome by 10%.
The sensitivity analysis, excluding the extreme values
(ACR = 2000 and ACR = 0), did not alter any conclu-
sions for either primary and secondary outcomes (Sup-
porting Information Tables S5 and S6). Supporting
Information Figures S1 and S2 show the predicted proba-
bility of maternal adverse composite outcomes for ACR
(Figure S1) and log ACR (Figure S2) based on the
Table 2. Number of maternal and neonatal adverse outcomes.
Values are numbers
Maternal adverse outcomes (Total n = 238)
Use of magnesium sulfate 12
Use of intravenous antihypertensives 15
Admission to HDU or ICU for hypertension 196
Abruption 7
Eclampsia 0
HELLP 8
Neonatal adverse outcomes (Total n = 192)
Iatrogenic preterm delivery <34 weeks 33
Birthweight <5th centile 98
Abnormal Dopplers (AEDF or REDF) 11
Arterial cord pH <7.1 12
Need for ventilation 32
Intrauterine death 5
Neonatal death 1
AEDF, absent end-diastolic flow; HDU, high dependency unit; HELLP,
hemolysis elevated liver enzymes low platelet count syndrome; ICU,
intensive care unit; REDF reversed end-diastolic flow.
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univariable and multivariable models excluding extreme
values (ACR = 2000 and ACR = 0). To illustrate the
appropriate fit of a linear relation between log ACR and
the log-odds of a maternal composite outcome, Figure 1
shows the unadjusted linear relationship alongside the
observed risk.
Discussion
Based on this retrospective cohort study, we show that
log ACR is an independent prognostic factor for compos-
ite adverse maternal and neonatal outcomes. We suggest
that a unit increase in log-transformed ACR is associated
with a 30% increased risk of maternal adverse composite
outcome and a 10% risk of neonatal adverse composite
outcome (corresponding to increased odds of 60 and
15%, respectively). We also demonstrated that in this
population a 1-unit increase in log ACR was associated
with a decrease in gestation at delivery by approximately
0.5 weeks (approximately 3 days).
Based on the secondary analyses we showed that
although ACR adds prognostic value, the overall
Table 3. Logistic regression results for unadjusted and adjusted models for the primary outcomes: composite maternal and composite neonatal
outcomes.
Model Variable
Composite maternal adverse outcome Composite neonatal adverse outcome
OR (95% CI) p-value ROC* OR (95% CI) p-value ROC*
Unadjusted ACR** 1.52 (1.38–1.68) <0.001 0.70 (0.66–0.74) 1.13 (1.02–1.25) 0.022 0.557 (0.504–0.610)
Adjusted ACR** 1.60 (1.42–1.80) <0.001 0.76 (0.72–0.80) 1.15 (1.02–1.29) 0.025 0.718 (0.668–0.760)
Gestational age at ACR 0.88 (0.83–0.92) <0.001 0.25 (0.16–1.29) <0.001
Maternal age 1.04 (1.08–1.08) 0.019 0.99 (0.95–1.02) 0.505
Essential hypertension 0.78 (0.38–1.60) 0.505 1.62 (0.79–3.33) 0.19
Preexisting diabetes 0.68 (0.12–3.72) 0.655 1.77 (0.40–7.88) 0.452
Gestational diabetes 1.02 (0.38–2.77) 0.964 0.73 (0.19–2.77) 0.64
Smoking 0.85 (0.50–1.45) 0.55 1.94 (1.16–3.26) 0.012
Nulliparity 0.96 (0.66–1.40) 0.826 1.16 (0.77–1.75) 0.471
Social deprivation index
1 1 1
2 0.80 (0.46–1.41) 0.451 0.95 (0.53–1.72) 0.876
3 1.10 (0.63–1.92) 0.73 0.78 (0.42–1.45) 0.437
4 0.623 (0.33–1.19) 0.152 0.78 (0.39–1.55) 0.473
5 0.424 (0.26–0.80) 0.008 0.84 (0.43–1.62) 0.603
Body mass index
<18.5 1 1
18.5–24.99 1.06 (0.32–3.50) 0.93 0.21 (0.07–0.64) 0.006
25.0–29.99 1.47 (0.44–4.93) 0.535 0.12 (0.04–0.38) <0.001
30.0–34.9 0.70 (0.20–2.48) 0.581 0.11 (0.03–0.37) <0.001
35.0–39.9 0.50 (0.13–1.98) 0.321 0.16 (0.04–0.57) 0.005
>40.0 0.56 (0.13–2.39) 0.434 0.09 (0.02–0.41) 0.002
Mean arterial blood pressure 1.02 (1.00–1.05) 0.041 0.99 (0.97–1.01) 0.381
ROC, receiver operating characteristic.
*C statistic.
**Log-transformed ACR (albumin creatinine ratio).
Figure 1. Graph of the predicted probability of maternal composite
adverse outcome against albumin (mg/L) creatinine (mmol/L) ratio
(ACR). The adjusted (red) and unadjusted (blue) models were fitted
using log e (ln)-transformed ACR and the logit was obtained using
the coefficients from the fitted model multiplied by the means/
medians of all other continuous adjustment factors, the most
common category of the categorical adjustment factors and the
values of log ACR. [Color figure can be viewed at
wileyonlinelibrary.com]
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discrimination performance of the multivariable models
was only moderate. Thus, additional prognostic factors
are required to improve performance further, for a clini-
cally useful model to identify those most likely to have an
adverse outcome. In terms of improving discrimination
performance (as measured by the C-statistic), ACR
appears to be more important for maternal outcomes
than for fetal outcomes.
A systematic review (25) and study that used ORs and
appropriate tests on two ACR thresholds (26) have
already indicated a prognostic ability of ACR for adverse
outcomes associated with preeclampsia. Nonetheless,
three of five of the studies included in the systematic
review (25) were conducted 30 years ago with ACR tests
that had different thresholds and that were performed in
heterogeneous populations (7). Previous work is also lim-
ited by the use of thresholds to categorize (or dichoto-
mize) ACR values (26). Other studies have found that the
degree of proteinuria does not correlate with adverse out-
come (6,27). A major strength and uniqueness of our
study was that ACR was analyzed as a continuous variable
(28). Categorization of continuous predictors leads to loss
of information, and hence loss of power, as well as poor
predictive performance, and hence poor clinical useful-
ness (29–31). It also leads to data dredging (to find the
“best” threshold) and does not reflect the underlying
prognostic trend.
A log transformation was identified as the most appro-
priate scale on which to incorporate ACR in the model,
suggesting that the effect of a 1-unit increase in ACR
depends on the actual value of ACR itself. Other strengths
include the use of stored samples to measure ACR using
standardized measurement methods, the collection of ACR
values blind to the outcome status, the reasonably large
cohort itself, and the very small amount of missing data.
This study had some limitations. The primary out-
comes were “composite” to increase the power to detect
the prognostic ability of ACR. Moreover, the outcomes
are objective, and clinical severity is similar within each
group. However, it is difficult to examine the effect size
of the prognostic factor of interest for each outcome sep-
arately (32). It is instead presumed that the effect size is
related to all the components of the composite outcome.
It is recommended that components of composite out-
comes be considered secondary outcomes and that the
related results are provided alongside primary analysis.
This was not possible in this study due to the small num-
ber of events in most of the components of the composite
outcome. However, these components were carefully
selected to ensure that they were comparable in magni-
tude of severity and direction of effect.
A further potential limitation results from the retro-
spective design of our study, as it is difficult to exclude
the possibility of intervention bias in observational studies
of this type. ACR results were available to clinicians, and
may have influenced management decisions and thereby
affected maternal and neonatal outcomes. However, these
effects are likely to be small, as decision-making in
women with preeclampsia is based on the whole clinical
presentation, not just the amount of proteinuria.
We have shown that in women with suspected
preeclampsia the ACR at presentation is an independent
predictor of adverse outcome. As an indication of the
potential usefulness of ACR in practice, Figure 1 shows
how the value of ACR would change the predicted proba-
bility of an adverse outcome for a woman who otherwise
would have median values of other covariates included in
our model. However, clinical management of women with
preeclampsia is directed by multiple factors, for example
BP control, hematological and biochemical parameters,
symptomatology and fetal considerations, including gesta-
tion. Thus, no single factor determines management or, in
particular, intervention via delivery. Our data suggest that
ACR should be considered within this clinical assessment.
A recent series on prognosis research (9–12) discusses
how a single prognostic factor (such as ACR) rarely pre-
dicts individual outcome risk accurately, and usually does
not suitably discriminate between high-risk and low-risk
individuals. This is why prognostic models are needed, as
they utilize multiple prognostic factors in combination to
improve individual risk prediction accuracy and to dis-
criminate better the underlying risk across individuals
(33). Future work should focus on identifying further
independent prognostic factors for adverse outcomes in
order to further improve the discrimination performance
of prognostic models. This may include the examination
of the prognostic value of multiple measurements of ACR
over time. In due course, a prognostic model could be
developed incorporating a large set of prognostic factors
(including ACR), followed by internal and external vali-
dation to ensure reliability of the model predictions. At
that stage, its use in clinical decision-making could be
evaluated, for example based on values of high predicted
risk that warrant clinical action.
Funding
There was no funding for this study. S.J.S. and F.D. are
supported by Tommy’s (registered charity nos 1060508
and SCO39280), who contribute to research infrastructure
costs.
References
1. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM,
Steyn W, et al. The classification, diagnosis and
ª 2017 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd
on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)., 96 (2017) 580–588
586
Urinary ACR and adverse outcomes E.G. Elia et al.
management of the hypertensive disorders of pregnancy: a
revised statement from the ISSHP. Pregnancy Hypertens.
2014;4:97–104.
2. Say L, Chou D, Gemmill A, Tuncalp €O, Moller A-B,
Daniels J, et al. Global causes of maternal death: a WHO
systematic analysis. Lancet Glob Health. 2014;2:e323–33.
3. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal
S, et al. Excess placental soluble fms-like tyrosine kinase 1
(sFlt1) may contribute to endothelial dysfunction,
hypertension, and proteinuria in preeclampsia. J Clin
Invest. 2003;111:649–58.
4. Nisell H, Trygg M, B€ack R. Urine albumin/creatinine ratio
for the assessment of albuminuria in pregnancy
hypertension. Acta Obstet Gynecol Scand. 2006;85:1327–
30.
5. Huang Q, Gao Y, Yu Y, Wang W, Wang S, Zhong M.
Urinary spot albumin: creatinine ratio for documenting
proteinuria in women with preeclampsia. Rev Obstet
Gynecol. 2012;5:9–15.
6. Cade TJ, de Crespigny PC, Nguyen T, Cade JR, Umstad
MP. Should the spot albumin-to-creatinine ratio replace
the spot protein-to-creatinine ratio as the primary
screening tool for proteinuria in pregnancy. Pregnancy
Hypertens. 2015;5:298–302.
7. Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD.
Diagnostic accuracy of spot urinary protein and albumin
to creatinine ratios for detection of significant proteinuria
or adverse pregnancy outcome in patients with suspected
pre-eclampsia: systematic review and meta-analysis. BMJ.
2012;345:e4342.
8. Baweja S, Kent A, Masterson R, Roberts S, McMahon LP.
Prediction of pre-eclampsia in early pregnancy by
estimating the spot urinary albumin: creatinine ratio using
high-performance liquid chromatography. BJOG.
2011;118:1126–32.
9. Riley RD, Hayden JA, Steyerberg EW, Moons KGM,
Abrams K, Kyzas PA, et al. Prognosis Research Strategy
(PROGRESS) 2: prognostic factor research. PLoS Med.
2013;10:e1001380.
10. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K,
Timmis A, et al. Prognosis research strategy (PROGRESS)
1: a framework for researching clinical outcomes. BMJ.
2013;346:e5595.
11. Hingorani AD, van der Windt DA, Riley RD, Abrams K,
Moons KGM, Steyerberg EW, et al. Prognosis research
strategy (PROGRESS) 4: Stratified Medicine Research.
BMJ. 2013;346:e5793.
12. Steyerberg EW, Moons KGM, van der Windt DA, Hayden
JA, Perel P, Schroter S, et al. Prognosis Research Strategy
(PROGRESS) 3: Prognostic Model Research. PLoS Med.
2013;10:e1001381.
13. Scottish Government. Scottish Index of Multiple
Deprivation 2012. Edinburgh: Scottish Government, 2012.
14. Cnossen JS, Vollebregt KC, de Vrieze N, ter Riet G, Mol
BWJ, Franx A, et al. Accuracy of mean arterial pressure
and blood pressure measurements in predicting pre-
eclampsia: systematic review and meta-analysis. BMJ.
2008;336:1117–20.
15. Scottish Intercollegiate Guidelines Network (SIGN).
Management of diabetes: a national clinical guideline
(Guideline 116). Edinburgh: SIGN, 2010 (Updated 2013).
16. Bonellie S, Chalmers J, Gray R, Greer I, Jarvis S, Williams
C. Centile charts for birthweight for gestational age for
Scottish singleton births. BMC Pregnancy Childbirth.
2008;8:1.
17. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein
AR. A simulation study of the number of events per
variable in logistic regression analysis. J Clin Epidemiol.
1996;49:1373–9.
18. Harrell FE. Regression modeling strategies, with applications
to linear models, survival analysis and logistic regression.
New York: Spring Science + Business Media, 2001.
19. Royston P, Altman DG. Regression using fractional
polynomials of continuous covariates: parsimonious
parametric modelling. Appl Stat. 1994;43:429–67.
20. Hernandez-Dıaz S, Toh S, Cnattingius S. Risk of pre-
eclampsia in first and subsequent pregnancies: prospective
cohort study. BMJ. 2009;338:b2255.
21. Duckitt K, Harrington D. Risk factors for pre-eclampsia at
antenatal booking: systematic review of controlled studies.
BMJ. 2005;330:565.
22. North RA, McCowan LME, Dekker GA, Poston L, Chan
EHY, Stewart AW, et al. Clinical risk prediction for pre-
eclampsia in nulliparous women: development of model in
international prospective cohort. BMJ. 2011;342:d1875.
23. Chappell LC, Enye S, Seed P, Briley AL, Poston L,
Shennan AH. Adverse perinatal outcomes and risk factors
for preeclampsia in women with chronic hypertension: a
prospective study. Hypertension. 2008;51:1002–9.
24. Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ,
Alemayehu D, Symonds T. Patient-reported outcomes:
measurement, implementation and interpretation. Boca
Raton: CRC Press, Taylor & Francis Group, 2014.
25. Thangaratinam S, Coomarasamy A, O’Mahony F, Sharp S,
Zamora J, Khan KS, et al. Estimation of proteinuria as a
predictor of complications of pre-eclampsia: a systematic
review. BMC Med. 2009;7:1.
26. Robb AO, French-Constant A, Morris RK, Denison FC,
Stock SJ. PMM.43. The predictive value of urinary
albumin: creatinine ratio in pregnancy. Arch Dis Child
Fetal Neonatal Ed. 2014;99(Suppl 1):A1–180.
27. Payne B, Magee LA, Co^te A-M, Hutcheon JA, Li J, Kyle
PM, et al. PIERS proteinuria: relationship with adverse
maternal and perinatal outcome. J Obstet Gynaecol Can.
2011;33:588–97.
28. Altman DG, Royston P. The cost of dichotomising
continuous variables. BMJ. 2006;332:1080.
29. Zhao LP, Kolonel LN. Efficiency loss from categorizing
quantitative exposures into qualitative exposures in case-
control studies. Am J Epidemiol. 1992;136:464–74.
ª 2017 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd
on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)., 96 (2017) 580–588
587
E.G. Elia et al. Urinary ACR and adverse outcomes
30. Altman DG, Lausen B, Sauerbrei W, Schumacher M.
Dangers of using “optimal” cutpoints in the
evaluation of prognostic factors. J Natl Cancer Inst.
1994;86:829–35.
31. Collins GS, Ogundimu EO, Cook JA, Manach YL, Altman
DG. Quantifying the impact of different approaches for
handling continuous predictors on the performance of a
prognostic model. Stat Med. 2016;35:4124–35.
32. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C.
Composite outcomes in randomized trials: greater
precision but with greater uncertainty. JAMA.
2003;289:2554–9.
33. von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB,
Co^te A-M, et al. Prediction of adverse maternal outcomes
in pre-eclampsia: development and validation of the
fullPIERS model. Lancet. 2011;377:219–27.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Maternal characteristics for women who
experienced maternal adverse composite outcome; values
are numbers and percentages unless otherwise stated.
Table S2. Maternal characteristics for neonatals who
experienced adverse composite outcomes; values are num-
bers and percentages unless otherwise stated.
Table S3. Linear regression results for the unadjusted
and adjusted model for the secondary outcome; gesta-
tional age at delivery.
Table S4. Poisson regression with robust SE results for
ACR (log-transformed) for unadjusted, adjusted models,
where the response is composite maternal/neonatal
adverse outcome.
Table S5. Logistic regression results with extreme ACR
values removed for log-transformed ACR for unadjusted
and adjusted models for the primary outcomes; compos-
ite maternal adverse outcome and composite neonatal
outcome.
Table S6. Linear regression results with extreme ACR
values removed for log-transformed ACR for the unad-
justed and adjusted model for the secondary outcome;
gestational age at delivery.
Figure S1. Graph of the predicted probability of mater-
nal composite adverse outcome (AO) against albumin
(mg/L) creatinine (mmol/L) ratio (ACR). The adjusted
(red) and unadjusted (blue) models were fitted using log-
transformed ACR and the logit was obtained using the
coefficients from the fitted model multiplied by the
means/medians of all other continuous adjustment fac-
tors, the most common category of the categorical adjust-
ment factors and the values of log ACR.
Figure S2. Graph of the predicted probability of mater-
nal composite adverse outcome (AO) against the log-
transformed albumin (mg/L) creatinine (mmol/L) ratio
(ACR). The adjusted (red) and unadjusted (blue) models
were fitted using log-transformed ACR and the logit was
obtained using the coefficient of log ACR from the fitted
model multiplied by the values of log ACR.
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